SCHEMBL17675673

SCHEMBL17675673

CCOC(=O)Cc1ccc(F)cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
CYP1A2 P05177 1/20 0.44
PDGFRB P09619 1/20 0.44
FGFR1 P11362 1/20 0.44
PDGFRA P16234 1/20 0.44
FLT1 P17948 1/20 0.44
FGFR3 P22607 1/20 0.44
KDR P35968 1/20 0.44
ALDH1A1 P00352 4/20 0.43
TDP1 Q9NUW8 2/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 2/20 0.43
KDM4E B2RXH2 1/20 0.42
PTGS2 P35354 2/20 0.42
ATM Q13315 1/20 0.41
GAA P10253 1/20 0.41
PDK1 Q15118 1/20 0.41
FBP1 P09467 1/20 0.40
PTGS1 P23219 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10473975 0.89 MAPT (0.50) MAPTPDGFRBFGFR1PDGFRAFLT1
SCHEMBL5062383 0.88 MAPT (0.52) MAPTCYP1A2ALDH1A1TDP1LMNA
SCHEMBL21824100 0.86 ALDH1A1 (0.59) MAPTCYP1A2ALDH1A1TDP1LMNA
SCHEMBL13400411 0.86 TSHR (0.49) MAPTCYP1A2PDGFRBFGFR1PDGFRA
SCHEMBL27719772 0.86 PDGFRB (0.56) MAPTCYP1A2PDGFRBFGFR1PDGFRA
SCHEMBL10653936 0.85 MAPT (0.49) MAPTCYP1A2ALDH1A1TDP1LMNA
SCHEMBL492505 0.84 CYP1A2 (0.64) MAPTCYP1A2ALDH1A1TDP1LMNA
SCHEMBL1695161 0.84 EGFR (0.48) MAPTCYP1A2PDGFRBFGFR1PDGFRA
SCHEMBL5201986 0.84 LMNA (0.49) MAPTCYP1A2PDGFRBFGFR1PDGFRA
SCHEMBL7226743 0.83 ALDH1A1 (0.50) MAPTCYP1A2PDGFRBFGFR1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110803992-B Preparation method of 3-nitro-4-fluoroacetophenone acetate 暨明医药科技(苏州)有限公司 2022-06-24 CN disclosed
CN-107108557-B Spirocyclic indolines for the treatment and prophylaxis of Respiratory Syncytial Virus (RSV) infection 瑞威有限公司 2020-11-10 CN disclosed
CN-110803992-A Preparation method of 3-nitro-4-fluoroacetophenone acetate 暨明医药科技(苏州)有限公司 2020-02-18 CN disclosed
EP-3204375-B1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) REVIRAL LTD (GB) 2019-02-13 EP disclosed
US-10106539-B2 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) ReViral Limited (GB) 2018-10-23 US disclosed
US-20170305908-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) ReViral Limited (GB) 2017-10-26 US disclosed
EP-3204375-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) Reviral Limited (GB) 2017-08-16 EP disclosed
WO-2016055780-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) RE:VIRAL LTD (GB) 2016-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305908-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) NR3C2, SAV1, ACE2 MAPT 4459/4885CYP1A2 585/4885PDGFRB 1557/4885
US-10106539-B2 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) SPTBN1, NR3C2, SPNS2 MAPT 4479/4885CYP1A2 568/4885PDGFRB 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.